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Abstract
Attempts to develop an efficient anti-staphylococcal vaccine in humans have so far been unsuccessful. Therefore, more
knowledge of the antigens that are expressed by Staphylococcus aureus in human blood and induce an immune response in
patients is required. In this study we further characterize the serial levels of IgG and IgA antibodies against 56 staphylococcal
antigens in multiple serum samples of 21 patients with a S. aureus bacteremia, compare peak IgG levels between patients
and 30 non-infected controls, and analyze the expression of 3626 genes by two genetically distinct isolates in human blood.
The serum antibody levels were measured using a bead-based flow cytometry technique (xMAPH, Luminex corporation).
Gene expression levels were analyzed using a microarray (BmG@s microarray). The initial levels and time taken to reach peak
IgG and IgA antibody levels were heterogeneous in bacteremia patients. The antigen SA0688 was associated with the
highest median initial-to-peak antibody fold-increase for IgG (5.05-fold) and the second highest increase for IgA (2.07-fold).
Peak IgG levels against 27 antigens, including the antigen SA0688, were significantly elevated in bacteremia patients versus
controls (P#0.05). Expression of diverse genes, including SA0688, was ubiquitously high in both isolates at all time points
during incubation in blood. However, only a limited number of genes were specifically up- or downregulated in both
isolates when cultured in blood, compared to the start of incubation in blood or during incubation in BHI broth. In
conclusion, most staphylococcal antigens tested in this study, including many known virulence factors, do not induce
uniform increases in the antibody levels in bacteremia patients. In addition, the expression of these antigens by S. aureus is
not significantly altered by incubation in human blood over time. One immunogenic and ubiquitously expressed antigen is
the putative iron-regulated ABC transporter SA0688.
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Introduction
Staphylococcus aureus is one of the most common causes of
bloodstream infections [1,2] and S. aureus bloodstream infections
are associated with serious complications such as infective
endocarditis and prosthetic device infection [3,4,5]. The mortality
rate of S. aureus bacteremia is approximately 20–30% [6,7,8].
Unfortunately, due to the increasing antibiotic resistance of clinical
S. aureus isolates [9,10] and the simultaneous decrease in the
number of newly approved antimicrobial agents [11,12], the
treatment of S. aureus bacteremia is becoming increasingly difficult.
Therefore, alternative strategies to prevent or treat S. aureus
bacteremia are much needed.
One potential strategy is the development of a vaccine.
However, despite the promising results of anti-staphylococcal
vaccines in animal models, efforts to develop an efficient vaccine
against S. aureus in humans have so far failed [13,14,15].
Classically, vaccine development has focused on stimulating the
humoral immune response during S. aureus infection, as this
response is considered to play an important role in clearing
infections [16]. Although recent work questions the effectiveness of
the humoral immune response in clearing infections [15] and
suggests a more important role for the Th17 cell-mediated
immune response [14,17], knowledge of which antigens are
expressed by bacteria and are immunogenic in infected patients
remains essential for new immunotherapies. However, to date the
number of reports exploring the immunogenicity of S. aureus
antigens, especially in humans, is limited and all of these studies
have investigated relatively small numbers of bacterial antigens
(reviewed in [16]. In short, two of the most recent studies found
detectable yet heterogeneous antibody levels in single serum
samples of both infected patients and healthy controls against 19
[18] or 8 [19] recombinant S. aureus antigens. Another study
analyzed the immunogenicity of whole-cell wall protein prepara-
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tions using 2-dimensional gel electrophoresis (2-DE) immunoblot-
ting of pooled sera from both infected patients and controls [20].
Fifteen immunogenic surface proteins were identified, including
SdrE and SA0688, for which significantly increased IgG levels had
previously been demonstrated in infected patients, compared to
non-infected controls [18]. In the most comprehensive study to
date, the antibody levels against 19 staphylococcal antigens were
serially measured in multiple serum samples from bacteremia
patients [21], and heterogeneity in the antibody levels between
different patients was again observed. IsdA was associated with
increased antibody levels in the majority of patients and was
therefore suggested as a potential vaccine component. However,
several antigens analyzed in earlier studies including wall teichoic
acid, peptidoglycan, SA0688, alpha toxin and other antigens
which are hypothesized to be important virulence factors were not
analyzed in this study.
To further characterize the humoral immune response during S.
aureus bacteremia, we analyzed the levels of IgG and IgA
antibodies against 56 staphylococcal antigens in serial serum
samples from 21 bacteremia patients. This is the largest collection
of known staphylococcal antigens analyzed to date, including the
non-protein antigens wall-teichoic acid and peptidoglycan. In
addition, we compared the IgG levels against all 56 antigens in
bacteremia patients and non-infected controls. Finally, to gain
further insight into the bacterial antigens that are expressed in
human blood and could be involved in the pathogenesis of
bacteremia, we studied the expression changes of 3626 S. aureus
genes during the incubation of two genetically distinct strains in
human blood using microarray analyses. Based on these investi-
gations and previous data, we discuss the potential of specific
staphylococcal antigens as components of human vaccines.
Materials and Methods
Ethics Statement
All patient serum samples used in this study were obtained from
coded left-over material from routine diagnostic blood samples. In
concordance with the guidelines of the Erasmus University
Medical Hospital and the Dutch federation of Biomedical
Scientific Societies (Federatie van Medische Wetenschappelijke
Verenigingen), all patients were informed of the possibility that
left-over material from diagnostic samples could be used for
scientific research and all patients were offered the opportunity to
give written refusal to this. Serum samples used in this study were
only obtained from patients who did not object to the use of left-
over material for scientific research and gave verbal consent for
this. This procedure was approved and the acquisition of
additional written consent was waived specifically for this
retrospective study by the Medical Ethics Committee of the
Erasmus University Medical Center Rotterdam (MEC-2007-106,
addendum 2). All collected serum samples were coded and only
qualified physicians of the department of Medical Microbiology
and Infectious Diseases had access to the original patient data.
Patients, Controls and Definitions
Twenty-one adult patients, admitted to the Erasmus Medical
Center between March 2007 and March 2011 were followed from
the time of diagnosis of S. aureus bacteremia until discharge from
the hospital or, if applicable, during outpatient appointments after
discharge. Bacteremia was defined as the isolation of S. aureus from
at least one blood culture set. A median number of 10
(interquartile range, 12) serum samples were collected per patient
over a median period of 25 (interquartile range, 37) days. The
median age of the bacteremia patients included in the study was 66
years (interquartile range, 10 years), of whom 71% were male.
All patients were treated with antibiotics according to hospital
guidelines under the supervision of a consultant of the Department
of Medical Microbiology and Infectious Diseases. During admis-
sion to the hospital, 4 of the 22 patients died; however, none of
these deaths could be directly attributed to staphylococcal
bacteremia.
Single serum samples were collected from 30 non-infected
patients, admitted to the Erasmus Medical Center between July
2011 and February 2012 for reasons other than any infectious
disease. All control patients did not suffer from any clinically
apparent infection in at least the past 6 months. The median age of
the non-infected control patients was 62 years (interquartile range,
11.5 years), of whom 80% were male. S. aureus nasal carrier status
was not tested for either the bacteremia patients or the control
group. However, previous results [22] and additional data (not
shown) suggest that there is no overall significant difference in the
IgG levels of persistent carriers and non-carriers for all of the
antigens tested in this study, except for TSST-1 and SasG.
S aureus Strains, Detection of Virulence Genes and
Genotyping
S. aureus isolates from bacteremia patients were identified on the
basis of colony and cellular morphology and Slidex Staph Plus
agglutination testing (bioMe´rieux, Marcy l’Etoile, France). The
identification of all staphylococcal isolates was confirmed by
Staphylococcus protein A (spa)-PCR [23]. The obtained PCR
fragments were sequenced; these sequences formed the basis of
spa-typing. All of the isolates were methicillin-sensitive, as
determined by the cefoxitin disk diffusion test according to the
Clinical and Laboratory Standards Institute (CLSI) criteria [24].
Antimicrobial susceptibility to additional antibiotics was deter-
mined using the VITEKH 2 system with card AST-P549
(bioMe´rieux).
For each of the 21 bacteremia patients, the first S. aureus isolate
obtained from a blood culture was screened using PCR for the
presence of the 54 genes encoding the antigens to which the
antibody responses were measured. PCR was not performed for
peptidoglycan and wall teichoic acid biosynthesis genes, as these
were assumed to be obligatorily present in all isolates. Primers
were both newly designed (Table 1) or described previously
[21,25]. In addition, pulsed-field gel electrophoresis (PFGE) was
performed on Sma1-digested chromosomal DNA from all 21
isolates, as described previously [26]. Relatedness among the
PFGE profiles was evaluated using Bionumerics software (version
3.0; Applied Maths, Ghent, Belgium).
Bacterial Antigens
All S. aureus antigens used for Luminex experiments were 66
His-tagged recombinant proteins with the exception of the
synthetic phenol-soluble modulin a 1–4 peptides and the sugars
petidoglycan and wall-teichoic acid. The following antigens were
coupled to xMAPH beads (Luminex Corporation, Austin, TX,
USA): protein secretion system ESX-1-associated factors EsxA and
B; Nuclease (Nuc); peptidoglycan hydrolase LytM; immunodomi-
nant antigen A (IsaA); glucosaminidase; lipase; peptidoglycan
(PG); wall teichoic acid (WTA); foldase-protein PrsA; clumping
factor A and B (ClfA and ClfB); SD-repeat containing proteins D
and E (SdrD and SdrE); iron-responsive surface determinants A
and H (IsdA and IsdH); fibronectin-binding proteins A and B
(FnbpA and FnbpB); extracellular fibrinogen-binding protein
(Efb); S. aureus surface protein G (SasG); staphylococcal comple-
ment inhibitor (SCIN); chemotaxis inhibitory protein of Staphylo-
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coccus aureus (CHIPS); formyl peptide receptor-like inhibitory
protein (FLIPr); phenol-soluble modulin a 1–4 peptides (PSM
alpha 1–4), alpha toxin; gamma-hemolysin B (HlgB); leukocidins
D, E, F and S (LukD, LukE, LukF and LukS); staphylococcal
enterotoxins A–E, G–J, M–O, Q, R (SEA–SEE, SEG-SEJ, SEM-
SEO, SEQ, SER); exfoliative toxins A and B (ETA and ETB);
toxic shock syndrome toxin 1 (TSST-1); staphylococcal superan-
tigen-like proteins 1, 3, 5, 9, 10 and 11 (SSL1, SSL3, SSL5, SSL9,
SSL10 and SSL11) and hypothetical proteins SA0104, SA0486
and SA0688. The following purified non-staphylococcal proteins
were also coupled to xMAP beads as negative controls: Moraxella
catarrhalis ubiquitous surface protein 1 (UspA1); Streptococcus
pneumoniae pneumococcal surface adhesin A (PsaA) and human
metapneumovirus surface protein (hMPV).
SasG, SdrD, SdrE, ClfB, IsdA, IsdH, FnbpA and FnbpB were
expressed and purified as described previously [27]. The
constructs were kindly provided by T. Foster (Trinity College,
Dublin, Ireland). Alpha toxin, HlgB, LukD, LukE, LukF, LukS,
SEA and SEC were prepared as described previously [28]. All
other proteins were kindly provided by other research groups, as
indicated in the acknowledgments.
The purity of all proteins was confirmed using SDS-page. The
antigens were coupled to xMAPH beads as described previously
[29,30] with some modifications for PG, WTA and PSM alpha 1–
4. For PG and WTA, the beads were incubated with the cross-
linkers adipic acid dihydrazide (ADH; 35 mg/ml) and EDC
(200 mg/ml) before incubation with the antigens according to the
standard protocol. For PSM alpha 1–4 peptides, the activated
beads were firstly coupled to 25 mg streptavidin per reaction
according to the standard protocol, and then subsequently coupled
to biotin-labeled PSM alpha 1–4 peptides for one hour.
Measurement of Anti-staphylococcal Antibodies
The levels of IgG and IgA antibodies against 56 staphylococcal
antigens in the serum samples of bacteremia patients were
measured using a bead-based flow cytometry technique (xMAPH;
Luminex Corporation), as previously described [21,29,30]. In
addition to staphylococcal antigens, the IgG levels against the non-
staphylococcal proteins UspA1 (Moraxella cattharalis), PsaA (Strepto-
coccus pneumoniae) and hMPV (human metapneumovirus) were also
determined. Serum samples were diluted 1:100 in PBS and
secondary phycoerythrin (PE)-labeled goat anti-human antibodies
against either total IgG or IgA were diluted 1:200. All
measurements were performed in duplicate and the median
fluorescence intensities (MFIs), a semi-quantitative measure of
antibody levels, were averaged. Duplicate measurements for which
the coefficient of variation was larger than 25% were excluded
from further analysis. All measurements were corrected for non-
Table 1. Newly designed primers used in this study.
Gene Forward Reverse
Alpha toxin CGGGATCCGCAGATTCTGATATTAATATT AACTGCAGTTAATTTGTCATTTCTTCTT
EsxA CTTACGGGCAAGGTTCAGAC CTTGTTCTTGAACGGCATCA
EsxB GGGTGGATATAAAGGTATTAAAGCA ATGGGTTCACCCTATCAAGC
ETA ACTGTAGGAGCTAGTGCATTTGT TGGATACTTTTGTCTATCTTTTTCATCAAC
ETB ACAAGCAAAAGAATACAGCG GTTTTTGGCTGCTTCTCTTG
FlipR TCGCTGCAGGTCTTTTAACTC GCTTTCTTCACATCACCTTGG
HlgB GTCAGAGAGTCCATAATGCATTTAA CACCAAATGTATAGCCTAAAGTG
IsaA ACCTGAAGCACCTGATGGGT TACGCAGCAGGTACAGGACA
Lipase CAATAGGCGTGGTGTCAGTG AATCGCCAACTTGTGGTTTC
LukDE TGAAAAAGGTTCAAAGTTGATACGAG TGTATTCGATAGCAAAAGCAGTGCA
LukF ATCATTAGGTAAAATGTCTGGACATGATCCA GCATCAA(GC)TGTATTGGATAGCAAAAGC
LukS GCAGACGCGTCAACACAA TTTTACATTTTCCCTATCTTTTT
LytM CATGCGAAAGACGCAAGCTG AGGCGCTGTTGAATTACCCG
Nuc TTATTAAGTGCTGGCATATGTATG TTTTCTAATATTAAATACACTTAC
PrsA AAGCAATACGGCGGTAAAGA GTGCGCCACCTTGTTTAAGT
SSL1 TTCAATTTTTGCATTTTGAGGTT TTCTTCATCTGAAGCGAAAGC
SSL3 TCGAGTATGACTTCAATTTGTGC GAACCACATCAACACAACTTCC
SSL5 GATGACAGCAATTGCGAAAG ATAGCCGCCATCTTTCATTG
SSL9 ATCGGCCAATGCAGAAGTAG CCACCGACCGAGTATTTGTC
SSL10 CAGCATTAGCAAAAGCGACA GCTTTCTATGACTTCCCCCATA
SSL11 GCACTAGGGATTTTAACAACAGG CCATGCGATGAGGCTGTAAT
SEC CTTGTATGTATGGAGGAATAACAA TGCAGGCATCATATCATACCA
SED GTGGTGAAATAGATAGGACTGC ATATGAAGGTGCTCTGTGG
SEE TACCAATTAACTTGTGGATAGAC CTCTTTGCACCTTACCGC
SEG CGTCTCCACCTGTTGAAGG CCAAGTGATTGTCTATTGTCG
SEH CAACTGCTGATTTAGCTCAG GTCGAATGAGTAATCTCTAGG
SEN CGTGGCAATTAGACGAGTC GATTGATTTGATGATTATAG
doi:10.1371/journal.pone.0053391.t001
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specific background signal by subtracting the MFIs of control
beads not coupled to any protein.
For the determination of immunological cross-reactivity, 1:200
diluted serum from one bacteremia patient with high MFIs for all
leukocidins was pre-incubated with recombinant proteins serially
diluted in PBS for 35 minutes on a thermomixer plate shaker.
After incubation the serum was spun down twice for 10 minutes at
3400 RPM and non-bound specific antibodies remaining in the
supernatant were measured following the standard protocol.
Microarray Experiments
Two S. aureus isolates from different bacteremia patients were
used for the microarray experiments. Overnight cultures were
diluted 100 times in fresh prewarmed brain-heart infusion (BHI)
broth and grown at 37uC in 5% CO2 until an OD590 of 0.5 was
reached. A volume of 30 ml of the culture was pelleted, and then
resuspended in 5 ml of freshly isolated heparinized human blood
or BHI broth, and incubated with gentle rotation at 37uC in 5%
CO2. All experiments were independently repeated twice with
blood from two healthy volunteers. Both volunteers were persistent
nasal carriers of S. aureus, which was confirmed with 3 positive
nasal swabs taken with a regular interval of 7 days over a period of
3 weeks. At time point 0 minutes for BHI and time point 0, 30, 60
and 90 minutes for blood, 10 ml RNA protect (Qiagen, German-
town, MD, USA) was added to the samples and incubated for 5
minutes at roomtemperature. The cultures were then pelleted,
cold water was added and subsequently 10 x concentrated PBS
was added. After centrifugation the pellets were lysed using 1 ml
RLT buffer (Qiagen) and 10 ml b-mercaptoethanol, and finally the
bacterial pellets were resuspended in 1 ml RNA Pro solution
(Qbiogene Inc., City, CA, USA).
S. aureus RNA was isolated using the FastRNAH Pro Blue Kit
according to the manufacturer’s instructions (Qbiogene Inc.) using
the Fastprep FP120 instrument (Qbiogene; two cycles of 45
seconds at a speed setting of 6.0). After isolation, the RNA was
treated with 6 U TURBO DNase (Ambion, Austin, TX, USA)
according to the manufacturer’s instructions, and then the RNA
was further purified using the RNAeasy kit (Qiagen) following the
manufacturer’s protocol.
Chromosomal DNA was isolated from overnight cultures grown
in BHI broth. Bacteria were lysed using FastProteinTM Blue
Matrix and the FastPrepH instrument (Qbiogene; two cycles of 45
seconds at a speed setting of 6.0). DNA was then purified using the
QIAamp DNA Mini Kit (Qiagen) and treated with 10 ml RNase
(Promega, Madison, WI, USA).
Hybridization probes were generated from 5 mg total RNA or
1 mg DNA according to the protocol of the Bacterial Microarray
Group (BmG@s; St. George’s Hospital Medical School, London,
UK). RNA or DNA was mixed with 3 mg random primers
(Invitrogen, Breda, The Netherlands), heat denatured and snap
cooled on ice. The RNA was reverse transcribed to cDNA to
incorporate the Cy5 dCTP (GE Healthcare, Diegem, Belgium)
fluorescent analog, and DNA was labeled with Cy3 dCTP (GE
Healthcare). Labeled RNA and DNA samples were pooled, and
hybridized overnight to an S. aureus microarray with PCR
amplicons printed on Ultragaps (Corning, NY, USA) glass slides
(BmG@S) [31]. The array design is available in BmG@Sbase
(Accession No. A-BUGS-17; http://bugs.sgul.ac.uk/A-BUGS-17)
and also ArrayExpress (Accession No. A-BUGS-17).
The microarray slides were scanned using the ScanArray
Express HT scanner (Perkin Elmer, Groningen, The Netherlands)
following the manufacturer’s instructions. The spots were quan-
tified using Imagene 6.0 software (BioDiscovery, Marina Del Ray,
CA, USA). The fully annotated microarray data have been
deposited in BmG@Sbase (accession number E-BUGS-137;
http://bugs.sgul.ac.uk/E-BUGS-137) (http://bugs.sgul.ac.uk/E-
BUGS-137%29) and also ArrayExpress (accession number E-
BUGS-137). GeneSpring GX version 7.3 Software (Agilent
Technologies, Santa Clara, CA, USA) was used for normalization
and further data analysis. Expression levels were quantified as the
log ratio of the signal derived from RNA isolated from blood
divided by the signal derived from DNA isolated from broth.
Expression levels were averaged for the duplicate experiments
from each blood donor, and then the average expression levels
from both donors were averaged.
Statistical Analysis
Fold-increases in antibody levels were calculated as the ratio of
the peak antibody level divided by the initial antibody level (as
measured in the first serum sample). If the antibody level only
declined after the initial measurement, than the ratio of the lowest
antibody level divided by the initial antibody level was calculated.
Both fold-increases and decreases were pooled to determine the
median fold-change in antibody levels per antigen.
Evaluation of histogram plots and the Kolmogorov-Smirnov test
revealed a non-normal distribution of the IgG levels for most
antigens. The non-parametric Mann-Whitney U test was used to
compare the antibody levels of bacteremia patients and controls.
Spearman’s correlation coefficient was used for correlation
analysis of the microarray data. P-values #0.05 were considered
statistically significant. All statistical analyses were performed using
SPSS version 15.0 (SPSS, Chicago, IL, USA) or Graphpad Prism
version 5 (Graphpad Inc. La Jolla, CA, USA).
Results
Genetic Typing and Presence of Virulence Genes in
Clinical S. aureus Isolates
PFGE analysis was performed on the first available S. aureus
isolates from all 21 bacteremia patients. The dendogram in
Figure 1 illustrates the overall lack of relatedness between the
isolates from different patients, with the exception of the isolates
from patients 4, 5 and 14. However, there was no epidemiological
relationship between these or any of the patients included in this
study. To further characterize the genetic background of the
clinical isolates, all strains were spa-typed. A broad range of spa-
types linked to different clonal clusters were observed, including
two unknown new spa-types. All of the isolates were methicillin-
sensitive.
For 54 of the 56 antigens analyzed in this study, the presence of
the corresponding genes was determined in all clinical isolates
using PCR. In addition to the biosynthesis genes for peptidoglycan
and wall teichoic acid which are obligatorily present in each
isolate, 11 genes were found to be ubiquitously present in all
isolates: alpha toxin, clumping factor A and B, glucosaminidase,
IsaA, IsdA, lipase, LytM, nuclease, PrsA and SA0688. Five genes
were present in only one isolate: exfoliative toxin A, leukocidins F
and S, and staphylococcal enterotoxins C and Q. Exfoliative toxin
B and enterotoxins E and H were not present in any of the isolates.
A summary of the number of isolates containing each gene is
presented in Table 2.
Anti-staphylococcal Antibodies in Bacteremia Patients
To study the humoral immune response against a wide array of
staphylococcal antigens in bacteremia patients, the total IgG and
IgA levels against 56 antigens were measured in serial serum
samples from 21 bacteremia patients. The IgG and IgA levels
against EsxA, PSM alpha 1–4 peptides, SA0104, SEI and SEJ, and
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additionally IgA levels against EsxB and SEO were excluded from
further analysis, due to the very low signal intensities with
coefficients of variation larger than 25% between duplicate
experiments.
In general, IgG levels directed against all antigens were already
detectable at the time of diagnosis and showed a temporal increase
in the majority of bacteremia patients. The increases in IgA levels
were generally many-fold lower than the increases in IgG levels.
The levels of antigen-specific IgG, and to a lesser extent IgA,
varied extensively in the first serum sample obtained from each
patient (median of 0 days after diagnosis; range, 0–5 days)
(Figure 2). The time taken to reach the peak antibody levels varied
widely between patients and antigens, and ranged from 7 to 86
days after diagnosis. The course of antibody levels after reaching
the peak height was generally characterized by a decrease back
towards the initial level and remaining at this level for up to 97
days after diagnosis (Figure 2).
For 15 antigens, an increase in IgG levels was observed at some
time point after the onset of bacteremia in 95 to 100% of all
patients: glucosaminidase, HlgB, IsaA, IsdA, lipase, leukocidins D,
E, S and F, nuclease, PrsA, SA0688, SCIN and SSL3 and 10
(Table 2). In contrast to these 15 antigens, only PrsA and Efb were
associated with increased IgA levels in 95 to 100% of all patients
(Table S1). However, due to the lower signal intensities and
coefficients of variation larger than 25% between duplicate
experiments, PrsA and Efb-associated IgA levels in the majority
of patients were excluded from further analysis. No other antigens
were associated with increased IgA and/or IgG levels in at least
95% of all patients.
When the increases in the IgG levels against each bacterial
antigen in individual patients were combined, the highest median
fold increase from the initial serum sample to the peak IgG level
was observed for SA0688 (5.17-fold increase; range, 0.74–56.96)
followed by PrsA (2.92-fold increase; range, 1.32–34.21; Figure 3,
Table 2). PrsA was also associated with the highest median fold
increase in IgA levels (3.92-fold increase, range, 1.02–20.83),
followed by SasG (2.51-fold increase; range, 0.63–13.02) and
SA0688 (2.07-fold increase; range, 0.67–11.31) (Table S2). All
other antigens showed median fold increases close to the overall
median increase of 1.33 for IgG and 1.42 for IgA.
The median fold increases in the IgG levels for the non-
staphylococcal control antigens UspA1, PsaA and hMPV were
1.21 (range 0.72–2.07), 1.32 (range 0.7–2.07) and 1.11 (range
0.89–1.79), respectively.
For 289 (35%) of the 832 observed increases in IgG levels, the
corresponding gene was not present in the S. aureus isolate from the
same patient as determined by PCR. Of these 289 ‘false-positive’
increases, 259 (90%) were observed for known excreted antigens,
mainly exfoliative toxins, enterotoxins and hemolysins. When all of
the initial-to-peak fold-increases were classified as occurring in
either the presence or absence of the corresponding genes in
respective isolates, an overall median fold increase of 1.37 (range,
0.85–18.07) was observed in the presence of corresponding genes
and 1.29 (range, 0.83–2.44) in the absence of corresponding genes.
Figure 1. Dendogram of clinical isolates. Pulsed-field gel electrophoresis data and spa-types of S. aureus isolates obtained from blood cultures of
21 bacteremia patients are shown.
doi:10.1371/journal.pone.0053391.g001
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Table 2. Overview of gene presence and associated IgG responses of bacterial antigens.
Antigen
No. of patients with
gene pos isolates (%)
No. of patients with
increase in IgG level (%)
Median fold increase from
initial to peak level (range)
Significant
difference p value
Alpha toxin 21/21 (100%) 19/21 (91%) 1.3 (0.9–3.46) ND ND
CHIPS 13/21 (62%) 15/17 (88%) 1.2 (0.4–2.95) no 0.271
ClfA 21/21 (100%) 17/19 (90%) 1.6 (0.02–6.09) yes 0.010
ClfB 21/21 (100%) 13/19 (68%) 1.1 (0.01–5.42) yes 0.036
Efb 20/21 (95%) 10/14 (71%) 1.6 (0.51–7.96) no 0.492
EsxA 21/21 (100%) CV.25% CV.25% ND ND
EsxB 14/21 (67%) 14/16 (88%) 1.4 (0.22–2.91) yes 0.022
ETA 1/21 (5%) 14/21 (67%) 1.4 (0.29–23.78) no 0.246
ETB 0/21 (0%) 14/20 (70%) 1.30 (0.29–23.78) no 0.738
FlipR 15/21 (72%) 17/20 (85%) 1.32 (0.43–8.02) yes 0.005
FnbpA 19/21 (91%) 13/14 (93%) 1.41 (0.04–5.15) no 0.181
FnbpB 6/21 (29%) 8/9 (89%) 1.39 (0.75–3.68) yes 0.052
Glucosaminidase 21/21 (100%) 20/20 (100%) 1.38 (1.02–25.75) yes ,0.0001
HlgB 16/21 (76%) 21/21 (100%) 1.26 (1.02–5.14) yes 0.001
IsaA 21/21 (100%) 19/20 (95%) 1.09 (0.9–13.2) yes 0.003
IsdA 21/21 (100%) 21/21 (100%) 1.74 (1.07–40.45) yes 0.005
IsdH 20/21 (95%) 15/17 (88%) 2.0 (0.62–6.6) yes 0.011
Lipase 21/21 (100%) 20/21 (95%) 1.34 (0.85–20.99) yes 0.002
LukD 15/21 (71%) 21/21 (100%) 1.37 (0.64–4.63) yes 0.008
LukE 15/21 (71%) 20/21 (95%) 1.3 (0.64–4.63) yes 0.004
LukF 0/21 (0%) 20/21 (95%) 1.54 (0.95–3.92) yes 0.0002
LukS 0/21 (0%) 21/21 (100%) 1.37 (1.02–4.99) yes 0.003
LytM 21/21 (100%) 18/21 (86%) 1.33 (0.25–32.08) no 0.768
Nuc 21/21 (100%) 20/20 (100%) 1.55 (1.0–9.48) yes 0.025
Peptidoglycan ND 18/20 (90%) 1.26 (0.3–4.53) yes 0.009
PrsA 21/21 (100%) 12/12 (100%) 2.92 (1.32–34.21) no 0.096
PSMa peptides 1–4 21/21 (100%) CV.25% CV.25% ND ND
SA0104 16/21 (76%) CV.25% CV.25% ND ND
SA0486 17/21 (81%) 7/9 (78%) 1.37 (0.46–3.43) yes 0.020
SA0688 21/21 (100%) 18/19 (95%) 5.17 (0.74–56.96) yes ,0.0001
SasG 11/21 (52%) 7/10 (70%) 1.17 (0.35–21.64) no 0.374
SCIN 20/21 (95%) 19/20 (95%) 1.39 (0.92–16.58) yes 0.0005
SdrD 17/21 (81%) 11/12 (92%) 1.37 (0.01–5.17) yes 0.049
SdrE 14/21 (67%) 16/18 (89%) 1.69 (0.7–14.59) no 0.405
SEA 2/21 (14%) 16/21 (76%) 1.16 (0.3–52.14) no 0.486
SEB 5/21 (24%) 6/8 (75%) 1.13 (0.28–5.21) no 0.203
SEC 1/21 (5%) 18/21 (86%) 1.11 (0.68–19.37) no 0.356
SED 2/21 (10%) 18/21 (86%) 1.39 (0.56–8.54) no 0.130
SEE 0/21 (0%) 15/20 (76%) 1.39 (0.51–7.29) no 0.327
SEG 11/21 (52%) 15/21 (71%) 1.13 (0.11–5.07) no 0.106
SEH 0/21 (0%) 13/21 (62%) 1.11 (0.08–3.8) no 0.329
SEI 11/21 (52%) CV.25% CV.25% ND ND
SEJ 2/21 (10%) CV.25% CV.25% ND ND
SEM 8/21 (38%) 8/12 (67%) 1.54 (0.12–7.79) no 0.080
SEN 10/21 (48%) 17/21 (81%) 1.34 (0.62–4.72) no 0.053
SEO 11/21 (52%) 10/14 (71%) 1.08 (0.098–2.03) no 0.111
SEQ 1/21 (5%) 5/10 (50%) 1.05 (0.03–1.42) no 0.334
SER 2/21 (10%) 14/20 (70%) 1.44 (0.46–10.09) no 0.298
SSL1 18/21 (86%) 17/21 (81%) 1.56 (0.7–11.21) yes 0.001
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Comparison of Anti-staphylococcal Antibodies in
Patients and Controls
To investigate the significance of the increased IgG levels
observed in bacteremia patients, the peak IgG levels of all 21
bacteremia patients were compared to the IgG levels of 30 non-
infected, age-matched control patients. The IgG levels directed
against 27 antigens were significantly higher in bacteremia patients
than the non-infected controls (Table 2). The antigens associated
with the most significant elevations in IgG levels in bacteremia
patients compared to controls were SA0688 (Figure 4) and
glucosaminidase (P,0.0001), the immune modulators SSL5
(P,0.0001), SSL1 (P =0.0007) and SCIN (P =0.0004), and the
toxins gamma-hemolysin B (P =0.0007) and leukocidin F
(P,0.0001).
In vitro Expression of Bacterial Antigens in Human Blood
To gain further insight into which bacterial antigens are
expressed in human blood and could be involved in the
pathogenesis of bacteremia, microarray experiments were per-
formed using the genetically distinct isolates from patients 1 and 3
(Figure 1) to measure the global changes in S. aureus mRNA
expression during culture in human blood. The mRNA expression
levels of 3626 S. aureus genes were measured during log-phase
growth in BHI broth and also after 0, 30, 60 and 90 minutes
culture in human blood. Compared to the transcriptomes at the
start of incubation in blood (0 minutes), only 86 out of the 3626
tested genes showed a two-fold or higher increase in mRNA
expression in both isolates at all time points (30, 60 and 90
minutes) when incubated in blood (Table S2). A majority of these
upregulated genes have an unknown/unclassified function, are
involved in carbon metabolism or are excreted lipoproteins
(Figure 5). The only known virulence factors for which mRNA
expression was upregulated after culture in blood were the IgG-
binding protein sbi and the gamma-hemolysin A and B precursors.
Thirty genes showed a two-fold or more reduction in mRNA
expression in both isolates at all time points, compared to the
transcriptomes of both isolates at the start of incubation in blood
(Table S2). These downregulated genes are also mainly involved in
cellular metabolism or have an unknown function (Figure 5).
Comparison of the transcriptomes at each individual time point
(30, 60 and 90 minutes) with the transcriptomes of both isolates at
the start of incubation in blood (0 minutes), revealed that a total of
360, 420 and 641 genes, respectively, were up- or downregulated
two-fold or more. The functional distribution of the differentially
expressed genes at each time point was similar to the functional
distribution of the differentially expressed genes at all time points
combined. In addition to the earlier mentioned upregulation of
hemolysin precursors, a more than two-fold upregulation of IsdA, -
B, -C and –F, FnbpA and B and ClfA was noted after 90 minutes
incubation in blood; whereas only IsdA, -B, -C, -D and FnbpA were
upregulated two-fold or higher after 60 minutes and only IsdC was
upregulated at least two-fold after 30 minutes, compared to the
transcriptomes of both isolates at the start of incubation in blood.
Compared to log-phase growth in BHI broth, only 7 of the 3626
analyzed genes showed a two-fold or higher increase in mRNA
expression in both strains at all time points (30, 60 and 90 minutes)
when cultured in blood: dihydrolipoamide succinyltransferase, the
sugar phospate antiporter uhpT, the murein hydrolase regulatory
gene IrgA and the transcripts encoding the putative proteins
SA0806, 0211, 0622 and 0761.
Of the 56 bacterial antigens for which the antibody responses
were characterized in bacteremia patients, microarray data for 35
genes was available for at least two time points per isolate. In
general, the mRNA expression levels of these 35 antigens,
quantified as the RNA:DNA log ratios, correlated significantly
between both isolates at all time points (P#0.001), indicating
similar expression levels for these specific 35 genes in both strains.
The mRNA expression levels of four genes were consistently high
in both isolates during log-phase growth in BHI broth and during
all measured time points (0, 30, 60 and 90 minutes) of culture in
blood: SA0688, IsaA, EsxA and SCIN (Table S3). In addition, the
mRNA expression level of PrsA was high at all time points, except
for the 90 minutes time point in one isolate. Compared to the
expression level during log-phase growth in BHI broth, none of
these 35 genes displayed a two-fold or higher mRNA expression
level at any time point during culture in blood.
Discussion
In this study we investigated the humoral immune response
against 56 staphylococcal antigens in bacteremia patients. Firstly,
Table 2. Cont.
Antigen
No. of patients with
gene pos isolates (%)
No. of patients with
increase in IgG level (%)
Median fold increase from
initial to peak level (range)
Significant
difference p value
SSL3 19/21 (91%) 20/21 (95%) 1.29 (0.9–3.87) yes 0.002
SSL5 21/21 (100%) 19/21 (90%) 1.90 (0.65–8.43) yes ,0.0001
SSL9 6/21 (29%) 17/21 (81%) 1.35 (0.77–10.15) yes 0.003
SSL10 14/21 (67%) 18/19 (95%) 1.42 (0.84–4.83) yes 0.046
SSL11 7/21 (33%) 19/21 (91%) 1.70 (0.67–8.67) yes 0.015
TSST1 3/21 (14%) 16/21 (76%) 1.34 (0.27–10.69) no 0.271
Wall teichoic acid ND 17/19 (89%) 1.12 (0.29–6.26) no 0.344
UspA1 ND 11/14 (79%) 1.21 (0.72–2.07) ND ND
PsaA ND 10/12 (83%) 1.32 (0.7–2.07) ND ND
hMPV ND 12/13 (92%) 1.11 (0.89–1.79) ND ND
Presence of genes in 21 isolates, initial-to-peak fold-increases in IgG levels and comparison of peak IgG levels in 21 bacteremia patients and 30 non-infected controls for
56 staphylococcal antigens and three non-staphylococcal control antigens. Patients for whom the duplicate measurements of the IgG levels had a CV larger than 25%
were excluded from the analysis. IgG levels for the antigens EsxA, PSM alpha 1–4 peptides, SA0104, SEI and SEJ were completely excluded because of very low signal
intensities with coefficients of variation larger than 25% for a majority of patients. ND: not determined.
doi:10.1371/journal.pone.0053391.t002
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we further demonstrate considerable variation in the IgA and IgG
levels of all patients at the time of diagnosis; the time taken to
reach peak antibody levels for each antigen in each patient was
also heterogeneous. These heterogeneous, highly individual
antibody responses are in line with previous data [18,19,21,32]
and will likely be the result of an individually unique interplay
between patients and genetically diverse S. aureus strains. Indeed,
parallel to the diversity of patient antibody responses we further
confirmed the presence of a large genetic diversity amongst the
infecting strains (figure 1).
The increases observed in the IgG levels of bacteremia patients
were generally many-fold higher than the increases in the IgA
levels. This may be explained either by hypothesizing that IgA
production is not induced by hematogenic bacterial challenge to
the same extent as IgG production, or that IgA levels may not alter
considerably in blood but may increase more locally on mucosal
surfaces. In any case, the relatively low IgA responses prompted us
to focus attention on the more dynamic IgG responses in
bacteremia patients.
The IgG levels against fifteen bacterial antigens, including well-
described virulence factors such as IsdA and gamma-hemolysin B,
were found to increase in at least 95% of the bacteremia patients.
Additionally, the peak IgG levels against these 15 antigens were
significantly higher in bacteremia patients than age-matched, non-
infected patients. The putative ABC transporter SA0688 and the
membrane-associated foldase PrsA were associated with the
highest median fold increase in IgG levels (5.17 and 2.92-fold,
respectively). Although other antigens were also associated with
significantly increased IgG levels in individual patients, these data
indicate that SA0688 and PrsA appear to be among the most
broadly expressed and immunologically recognized antigens. This
observation is in line with previous studies which demonstrated the
immunogenicity of SA0688 in human serum [18,20]. In addition,
the antigen SA0688 showed promising results as part of a
multivalent vaccine in an animal model of osteomyelitis [25].
Unfortunately, nothing is currently known about the exact
function of SA0688 and how antibodies could interfere with
staphylococcal infection by binding this antigen. Moreover, in
general other antigens than SA0688 or PrsA which were not
Figure 2. Antibody courses against the antigen SA0688 in bacteremia patients. A: Courses of anti-SA0688 IgG levels in 21 bacteremia
patients. Each data point represents the average of duplicate Luminex measurements expressed as the mean fluorescence intensity (MFI). Each
patient is represented by a serial set of the same symbols and a polynomial trend lines is drawn through this set. B: Course of anti-SA0688 IgA levels
in 21 bacteremia patients. Note that the MFI values on the Y-axis are a factor of 10 lower than in Figure 2A.
doi:10.1371/journal.pone.0053391.g002
Figure 3. Initial-to-peak fold-increases in IgG levels for 6 bacterial antigens in bacteremia patients. Each data point represents a single
patient; the median fold-increase in IgG levels and interquartile range are represented by lines. Patients for whom the duplicate Luminex
measurements had a CV .25% were excluded from the analysis. Note the log10 scale of the y-axis.
doi:10.1371/journal.pone.0053391.g003
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associated with significantly increased antibody levels in this study
may also provide interesting targets for a vaccine, although we can
only speculate about these antigens based on our data and
previous studies.
In addition to the question which antigens should ideally be
selected for a vaccine component, we can only speculate about
whether or not the associated antibody responses will be protective
against infection. We observed clearly detectable, pre-existent IgG
levels against all antigens in patients at the time of diagnosis, which
is in line with previous observations of stable, pre-existent IgG
levels in both bacteremia patients and healthy controls [21,27,32].
These observations suggest that all individuals have an immuno-
logical memory specifically against S. aureus, possibly due to earlier,
(sub)clinical infections. It remains a question whether a further
increase in these pre-existent IgG levels will have an additional
protective effect against infection, even though this increase is
significant for diverse antigens such as SA0688 and PrsA
compared to non-infected controls. In any case, the significant
increases in IgG levels against diverse antigens suggests that these
antigens are being expressed in vivo in patients, which will be a pre-
requisite for any potential vaccine target.
To gain further insight into which bacterial antigens are
expressed in human blood, the global changes in the mRNA
expression levels of two genetically distinct S. aureus isolates during
incubation in human blood were investigated. In general, of the
3626 genes investigated, we could only associate limited numbers
of genes with significantly altered mRNA expression levels
specifically during incubation in blood, compared to the
transcriptomes of each isolate at the start of incubation in blood
or BHI broth. As noted for 35 of the 56 antigens investigated in
this study, most of the corresponding genes had a relatively
constant RNA:DNA log ratio at all time points during culture in
blood (Table S3). Most notably, the antigens SA0688, IsaA, EsxA,
SCIN and, with the exception of one measurement, PrsA were
highly expressed in both isolates in BHI broth and blood over
time. This stable expression of genes by genetically distinct isolates
in human blood or tissue would be a first prerequisite for any
antigen to be a potential vaccine component.
Most of the genes which were up- or downregulated in S. aureus
specifically during incubation in blood belong to functional classes
involved in cellular metabolism or have an unknown function.
Exceptions to this were the IgG-binding protein sbi and gamma-
hemolysin component A precursor, which were upregulated in
both isolates at all time points (30, 60 and 90 minutes) in blood
compared to the start (0 minutes). In addition, other genes were
upregulated at specific time points, mainly surface proteins such as
FnbpA, ClfA and the diverse iron-regulated surface determinant
(Isd) proteins. These findings are in agreement with a previous
study which reported that a limited number of S. aureus genes
encoding known virulence factors were specifically upregulated in
blood [33]. In this study, mRNA expression of the gamma-
hemolysin subunits were found to be most significantly upregu-
lated during incubation in blood.
Although our study demonstrates the in vitro expression and
in vivo immunogenicity of several antigens, there are several
limitations in regard to the used techniques. Firstly, in regard to
the bead-based flow cytometry assay, we used recombinant
staphylococcal antigens in our assay which may lack certain
naturally-occurring antibody-binding epitopes or may not have
been optimally coupled to our assay beads, thereby possibly
missing increases in the levels of specific antibodies. This could
provide an alternative explanation for the low signal intensities
observed for EsxA, PSM alpha 1–4 peptides, SA0104, SEI and
SEJ. Secondly, we observed significant increases in the antibody
levels against leukocidins S and F, for which corresponding genes
Figure 4. Comparison of anti-SA0688 IgG levels in bacteremia
patients and non-infected controls. Peak IgG levels of 21
bacteremia patients were compared to IgG levels of 30 non-infected
controls. The median value and interquartile range are represented by
lines. Note the log10 scale of the y-axis.
doi:10.1371/journal.pone.0053391.g004
Figure 5. Functional distribution of genes with altered mRNA expression in human blood. The functional classes are shown for which the
largest number of genes showed an at least twofold increased or decreased mRNA expression at all timepoints in blood (30, 60 and 90 minutes) in
both strains compared to trancriptomes at the start of incubation in blood (0 minutes). Functional classes for which only one gene showed significant
alterations in mRNA expression in blood are not shown.
doi:10.1371/journal.pone.0053391.g005
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were not present in any isolate. The increases in specific IgG for
these two leukocidin components may be the result of immuno-
logical cross-reactivity, where antibodies specific to one toxin
component may cross-react with structurally similar components
[34,35,36]. We confirmed the presence of immunological cross-
reactivity between the leukocidins F and D and gamma-hemolysin
B in our assay (Figure S1). No cross-reactivity was observed
between the enterotoxins in our assay (data not shown).
We observed a median fold-increase in IgG levels of 1.29 for all
‘false-positive’ increases where the corresponding genes were
absent. This median ‘false-positive’ increase was comparable to
that of all cases where corresponding genes were present (1.37) and
the overall median fold-increase of 1.33. In addition, these
increases were also comparable to those of the non-Staphylococcal
control antigens UspA1, PsaA and hMPV (1.21, 1.32 and 1.11
fold-increase, respectively). This apparent background signal could
on one hand be explained by a broad, non-specific rise in antibody
levels during infection or, alternatively, by the statistical phenom-
enon that the maximum value of an extended time course will
always be higher than single measurements. Indeed, although IgG
levels tend to remain constant over time in both healthy persons
[27] and up to three years after infection (unpublished data), small
variations in measured IgG levels are consequently observed. This
could explain the observed non-specific rise in antibody levels.
In regard to the micro array data, one limitation is that we
investigated antigen expression in just two out of 21 strains.
Investigating antigen expression in more strains would allow for
more robust conclusions about global changes in bacterial
transcriptomes, however we feel that we were able to gain more
insight into the expression of specific genes with our current,
rather technically demanding micro-array experiments. Secondly,
as with other in vitro models the question remains how well our
blood infection model reflects the in vivo situation during a
bacteremia. Especially the high dose of bacteria used is likely
different from the in vivo situation and could influence bacterial
mRNA expression. Finally, in regard to the expression of antigens
for which we characterized antibody responses, it should be noted
that any direct correlation of in vitro bacterial gene expression with
the in vivo immune response in patients should be interpreted with
caution. The mode and phase of bacterial growth in vivo may be
different and more diverse than the pattern of growth in vitro. In
addition, the expression of a bacterial antigen does not necessarily
induce an antibody response in vivo, either due to immune
modulation by the bacterium or the complex regulatory immune
processes within the host. Nonetheless, data on both bacterial gene
expression in vitro and the in vivo immune response can yield
valuable insight into the pathogenesis of infection and complement
each other for the identification of potential vaccine targets.
To summarize, our study suggests that most of the staphylo-
coccal antigens tested, including many known virulence factors, do
not lead to uniform increases in the antibody levels in bacteremia
patients. In addition, the expression of these antigens by S. aureus is
not significantly altered by incubation in human blood over time.
One immunogenic antigen is the putative iron-regulated ABC
transporter SA0688, which induced a significant antibody
response in all bacteremia patients and was stably expressed by
genetically distinct isolates under different culture conditions. The
ubiquitous expression of this antigen will be a prerequisite for any
potential vaccine target and our data, together with previous
literature, suggest that SA0688 could be a potential vaccine target.
Supporting Information
Figure S1 Cross-reactivity between leukocidins F and D
and hemolysin gamma-B in human serum. A: Serial
dilutions of recombinant leukocidin F (LukF) were pre-incubated
with the serum from a non-infected control with high IgG levels
against LukF. After incubation, the remaining IgG levels specific
against Leukocidins D, E, F and S and Hemolysin gamma-B were
measured. Note the loss in IgG levels specific for LukD and HlgB
at lower dilutions of LukF, suggesting immunological cross-talk
between these toxin components. B: The same experiment as for
Figure S1 A, now with serum from a different non-infected
control.
(TIF)
Table S1 Overview of gene presence and associated IgA
responses of bacterial antigens. Presence of genes in 21
isolates and initial-to-peak fold-increases in IgA levels in 21
bacteremia patients for 56 staphylococcal antigens. Patients for
whom the duplicate measurements of the IgA levels had a CV
larger than 25% were excluded from the analysis. IgA levels for
the antigens EsxA, EsxB, PSM alpha 1–4 peptides, SA0104, SEI,
SEJ and SEO were completely excluded because of very low signal
intensities with coefficients of variation larger than 25% for a
majority of patients. ND: not determined.
(DOC)
Table S2 List of genes with altered mRNA expression in
human blood. Genes are listed for which mRNA expression is
respectively at least twofold increased or decreased in both isolates
during all time points (30, 60 and 90 minutes) of culture in blood
compared to the transcriptomes at the start of culture in blood (0
minutes). mRNA expression is quantified as the average
RNA:DNA log ratio of duplo experiments in separate blood
samples of two blood donors. Ranges of RNA:DNA log ratios
between duplo experiments in separate blood samples are given,
unless only a single measurement from one blood sample was
available.
(DOC)
Table S3 mRNA expression levels of 35 genes in two
isolates during culture in human blood and log-phase
growth in BHI broth. Average RNA:DNA log ratios of
duplicate experiments in two separate blood samples are given;
dark (red) cells indicate a RNA:DNA ratio larger than 2 (i.e. high
expression) and gray (blue) cell indicates a RNA:DNA ratio
smaller than 0.5 (i.e. low expression). Range of RNA:DNA log
ratios between duplo experiments in seperate blood samples are
given, unless only a single measurement from one blood sample
was available.
(DOC)
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